Last updated 1 month ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.
The bilateral health cooperation agreement between the United States and the Republic of Uganda on December 10, 2025, is an important moment in the history of international development.
While the headline figure of $1.7 billion in US financing suggests continuity with the massive health interventions of the past two decades, the structural, ideological, and operational mechanisms of the deal represent a radical rupture.
This agreement is a renewal of the President’s Emergency Plan for AIDS Relief (PEPFAR) and also the flagship implementation of the Trump Administration’s “America First Global Health Strategy” (AFGHS), a doctrine that subordinates humanitarian outcomes to national security imperatives, commercial reciprocity, and a rigidly defined concept of sovereign responsibility.
For over twenty years, the United States maintained a “golden consensus” on global health, largely insulated from the partisan volatility of domestic politics. Agencies like the U.S. Agency for International Development (USAID) and programs like PEPFAR operated under a mandate that prioritized service delivery, broad population coverage, and the engagement of civil society.
The events of 2025, culminating in the dissolution of USAID and the centralization of aid functions within the Department of State, have shattered this consensus.
The new US-Uganda deal represents this new era—a “sovereign partnership” that eschews the donor-recipient dynamic in favor of a transactional compact designed to open markets for American industry, counter Chinese influence, and force fiscal graduation upon developing nations.
The Dismantling of USAID
To understand the mechanics of the December 2025 Kampala agreement, you need to analyze the systematic deconstruction of the US foreign assistance apparatus that preceded it. The year 2025 witnessed the most aggressive restructuring of US foreign policy institutions since the end of the Cold War.
The Dissolution Process
The most consequential event of 2025 was the operational dissolution of the United States Agency for International Development. Following an executive order on January 20, 2025, which froze foreign assistance pending a “90-day review,” the administration initiated a purge of the agency’s functions.
By March 28, the administration had notified Congress of its intent to “permanently dissolve” USAID, a move justified by claims that the agency had become a vehicle for “ideology,” “waste,” and “alarming inefficiencies.”
The impact was immediate and catastrophic for the traditional development sector. By August 1, 2025, approximately 86% of USAID’s nearly 6,200 active awards globally had been terminated.
The agency, which once employed nearly 10,000 staff, was reduced to a skeleton crew of legally required positions before its remaining functions were formally folded into the Department of State on July 1, 2025.
This was not a mere bureaucratic reshuffle—it was an ideological purge designed to centralize control over foreign aid within the diplomatic corps, ensuring that every dollar spent was directly aligned with short-term national interests rather than long-term development goals.
For Uganda, a nation where USAID had funded everything from malaria nets to parliamentary democracy programs, the shutdown created a vacuum. Implementing partners—primarily large international Non-Governmental Organizations (NGOs) like Chemonics and Abt Associates—found themselves cut off, with 71% reporting the cancellation of at least one category of activity by mid-year.
This cleared the field for the new “America First” architecture to take root.
The New Bureau
In the vacuum left by USAID, the State Department’s Bureau of Global Health Security and Diplomacy (GHSD) emerged as the primary architect of US health policy. Led by Dr. John N. Nkengasong and supported by senior advisors like Brad Smith (formerly of the “Department of Government Efficiency” or DOGE), the Bureau was tasked with operationalizing the new strategy.
The GHSD’s mandate differs fundamentally from that of a development agency. Its focus is explicitly diplomatic and securitized. The bureau integrates global health security as a “core component of U.S. national security,” viewing infectious disease control not as a humanitarian charity but as a form of “biodefense” for the American homeland.
This shift explains the structure of the Uganda deal, which prioritizes surveillance data and outbreak response over broad social welfare programs.
The “America First” Strategy
The intellectual framework for the Uganda deal was unveiled on September 18, 2025, with the release of the “America First Global Health Strategy.” The document rejects the “globalist” approach of multilateral cooperation in favor of “bilateralism,” “burden-sharing,” and “commercial reciprocity.”
The strategy is built on three pillars, which directly dictated the terms of the Uganda negotiation:
Pillar I: Safer
The primary goal of the strategy is to “protect the homeland.” This is achieved by pushing the US defensive perimeter outward. The strategy calls for “global surveillance systems” that can rapidly detect outbreaks “before they reach U.S. shores.”
In the Uganda deal, this manifests as heavy investment in laboratory systems and data sharing, effectively turning the Ugandan health system into an early warning sensor for the United States.
Pillar II: Stronger
This pillar focuses on eliminating “dependency.” The strategy mandates that US assistance be time-bound and contingent upon “meaningful co-investment” from recipient nations. The era of open-ended grants is over; the new model is the “compact,” a term borrowed from the Millennium Challenge Corporation but applied here with greater geopolitical conditionality.
The goal is to force countries like Uganda to “graduate” from aid, regardless of their readiness.
Pillar III: Prosperous
Perhaps the most radical departure is the explicit linkage of health aid to the US economy. The strategy seeks to “promote American health innovation” and “create jobs in America” by mandating the procurement of US-manufactured goods.
Foreign aid is thus reimagined as export promotion, using taxpayer dollars to subsidize the market entry of American pharmaceutical and technology companies into developing markets.
The Deal Structure
The “Bilateral Health Cooperation Memorandum of Understanding” signed in Kampala is the first major test case of this strategy in Africa, alongside similar agreements with Kenya and Rwanda. The financial and operational terms reveal the high stakes of this new partnership.
The Money
The agreement outlines a total investment envelope of approximately $2.3 billion over five years (2025–2030).
| Funding Source | Amount | Strategic Intent |
|---|---|---|
| United States Government | Up to $1.7 Billion | Support for HIV/AIDS, TB, Malaria, and Global Health Security. Focus on “frontline” commodities and surveillance. |
| Government of Uganda (GoU) | $577 Million | “Co-investment” to assume costs of human resources and domestic supply chain management. |
| Total Deal Value | $2.277 Billion | Comprehensive health system transition. |
The US Commitment: The phrase “up to $1.7 billion” is crucial. Unlike previous multi-year commitments which were often treated as floors, this figure functions as a ceiling. The disbursement is likely contingent on annual performance reviews and the satisfaction of “clear performance metrics.”
The funding is strictly siloed. The AFGHS explicitly states that the US will fund “100% of frontline commodity purchases” and “100% of frontline healthcare workers” in the short term, but will “rapidly decrease” funding for non-frontline activities such as technical assistance, advocacy, and overhead.
This represents a “hollowing out” of the aid package, focusing purely on the biological consumables (pills and test kits) while stripping away the ecosystem support that often made delivery possible.
Uganda’s Co-Investment: The requirement for Uganda to invest $577 million represents a massive fiscal escalation for the Museveni administration. Historically, Uganda has allocated between 6% and 9% of its national budget to health, well below the 15% target set by the Abuja Declaration.
The $577 million commitment forces the Ministry of Finance to find approximately $115 million in new fiscal space annually. Given Uganda’s rising debt-to-GDP ratio and the pressures of infrastructure servicing, this “co-investment” risks crowding out other sectors or leading to increased borrowing.
However, from Washington’s perspective, this is the “skin in the game” necessary to end the “moral hazard” of aid dependency.
Supply Chain Transition
A central tenet of the deal is the transition of commodity procurement from US-managed parallel systems to the Government of Uganda.
Under the PEPFAR model, the US government often purchased antiretrovirals (ARVs) centrally and distributed them through US contractors (like Chemonics), bypassing the Ugandan National Medical Stores (NMS) to ensure accountability. The new MOU mandates that procurement responsibilities “transition from the U.S. government to partner governments gradually.”
Strategic Implication: This is a victory for Ugandan sovereignty, a long-standing demand of President Museveni. It theoretically strengthens national institutions.
Operational Risk: The State Department’s own internal audits in 2025 found that “half of vendors visited were selling stolen donor-funded health commodities” in similar contexts.
By shifting procurement to local systems without the oversight previously provided by USAID contractors, the risk of massive diversion and stock-outs increases significantly. The AFGHS attempts to mitigate this by retaining direct US procurement for “American innovations,” creating a bifurcated supply chain: high-value US tech stays under US control, while basic commodities become Uganda’s problem.
Workforce Transition
Perhaps the most complex logistical challenge is the workforce transition. The US has effectively been the largest employer of health workers in Uganda for decades, paying salaries for thousands of clinical officers, nurses, and lab technicians through NGOs.
The MOU mandates a process to:
- Map all US-funded frontline workers
- Integrate them into the Ugandan public service cadres
- Transition them to the GoU payroll over five years
For example, the US plans to train and equip 14,000 Community Health Extension Workers (CHEWs), but the Ministry of Health must assume their stipends in a “phased manner.”
This creates a “fiscal cliff” for the Ugandan government. If the GoU fails to absorb these workers by year five, the health system could face a sudden workforce collapse. The “America First” strategy is betting that the threat of collapse will force the Ugandan treasury to prioritize health spending over other political patronage networks—a gamble with high stakes for the average Ugandan patient.
Commercial Statecraft
The US-Uganda deal is distinguishable from its predecessors by its unabashed mercantilism. The “Prosperous” pillar of the AFGHS dictates that foreign aid must deliver returns for the American economy. This has transformed the health agreement into a vehicle for US corporate expansion in East Africa.
The “Buy American” Mandate
The State Department has explicitly stated that the strategy “promotes the procurement and distribution of goods from US companies.” This marks a departure from the “best value” procurement rules that often favored generic manufacturers in India or South Africa.
The new logic argues that “American quality” justifies higher costs and that aid dollars should circulate back to the US industrial base.
Gilead and Lenacapavir
The crown jewel of this commercial diplomacy is the partnership with Gilead Sciences regarding Lenacapavir, a breakthrough twice-yearly injectable for HIV prevention.
On September 4, 2025, the Trump Administration announced a “new initiative” with Gilead to rollout this drug in ten high-burden countries, including Uganda. The US government used its monopsony power to provide a “pre-market advance commitment,” effectively de-risking Gilead’s investment.
Market Entry: By including Lenacapavir in the $1.7 billion package, the US government is subsidizing the entry of a patented, high-cost American drug into the Ugandan market.
Dependency: Unlike daily oral PrEP, which is available as a cheap generic, Lenacapavir is a proprietary technology. While Gilead has signed royalty-free licenses for generics, the initial years of the rollout will rely on US-manufactured supply. This locks the Ugandan HIV response into a dependency on American intellectual property.
Narrative: Senior Official Jeremy Lewin described this as “championing this American biomedical achievement.” The health benefit (reduced transmission) is inextricably linked to the commercial benefit (market share for Gilead).
Zipline Drones
The deal also heavily integrates Zipline International Inc., a California-based drone logistics company. While Zipline has operated in Rwanda since 2016, the 2025 agreements with Rwanda ($228 million) and Uganda formalize the company’s role as a direct beneficiary of US foreign assistance.
The State Department announced an agreement to provide up to $150 million to Zipline to expand operations across five countries, including Kenya and Rwanda (and by extension, the regional ecosystem including Uganda).
Strategic Function: The deal pays a US tech firm to manage the “last mile” delivery of blood and vaccines. This replaces the labor-intensive systems (often managed by local NGOs or drivers) with “American-made advanced robotics.”
Geopolitical Angle: This serves as a counter-narrative to Chinese infrastructure. While China builds roads (which degrade), the US exports “autonomous logistics” and “AI.” It’s a branding exercise as much as a logistical one, positioning the US as the partner of the “future.”
The Faith-Based Pivot
The most controversial aspect of the US-Uganda deal is the dramatic shift in who implements the aid. The AFGHS is driven by a deep skepticism of secular international NGOs and a preference for Faith-Based Organizations (FBOs), aligning with the conservative social values of both the Trump administration and the Museveni government.
Church-Run Healthcare
The MOU explicitly highlights “support for faith-based healthcare providers” as a key pillar. The administration justifies this by noting that FBOs—specifically the Catholic and Protestant medical bureaus—account for over 50% of health delivery capacity in Uganda.
The Winners: The Uganda Catholic Medical Bureau (UCMB) and the Uganda Protestant Medical Bureau (UPMB) are the primary beneficiaries. Following the aid freeze in early 2025, these organizations received “limited waivers” to continue services while secular NGOs remained defunded.
The new deal institutionalizes this preference. Funding will flow through “performance-based service agreements” directly to these bureaus.
Ideological Alignment: This shift bypasses the “woke” ideology that the Trump administration claims pervades secular development aid. It also strengthens the US relationship with powerful religious constituencies in Uganda, who are key political pillars of the Museveni regime.
The LGBTQ+ Crisis
The interplay between the new aid model and Uganda’s Anti-Homosexuality Act (AHA) creates a dangerous paradox. The AHA, enacted in 2023, criminalizes LGBTQ+ identity and has led to a crackdown on services for these groups.
The “Frontline” Trap: The AFGHS restricts funding to “frontline commodities” and “healthcare workers.” It explicitly defunds “soft” programs such as human rights advocacy, legal defense for arrested patients, and sensitivity training.
Impact: LGBTQ+ advocacy groups like Sexual Minorities Uganda (SMUG) warn that this leaves them defenseless. Without funding for “safe” drop-in centers or legal aid, LGBTQ+ individuals are terrified to access public or FBO-run clinics, fearing they will be reported to the police under the AHA mandates.
FBO Exclusion: By channeling funds through FBOs, many of which openly support the AHA and view homosexuality as a sin, the US is effectively building a health system that is structurally hostile to Men who have Sex with Men (MSM).
Given that MSM are a high-risk group for HIV, this policy undermines the very epidemiological goals the US claims to pursue. The strategy prioritizes the supply of drugs over the access environment, ignoring the reality that stigma kills as effectively as the virus.
The China Factor
The US-Uganda deal is a move on the chessboard of Great Power competition. The “America First” strategy is designed to counter the People’s Republic of China (PRC) in East Africa, using health as a wedge issue.
Chinese Tensions
Late 2025 saw a cooling of relations between Uganda and China in the health sector. Reports indicated that a Chinese medical team declined to donate equipment to the China-Uganda Friendship Hospital in Naguru, citing “political tensions.”
While China continues to send medical teams (the 25th team arrived in September 2025) and hold free medical camps in oil-rich regions like Kikuube, the US perceived an opening.
The US Counter-Offer
The US deal is crafted to contrast sharply with the Chinese model.
Data Sovereignty vs. Surveillance: The US emphasizes “integrated data systems.” While the US frames this as health security, it also serves to lock Uganda into US data standards, preventing the integration of Chinese Huawei-backed health surveillance systems.
The “biothreat radar” requires US access to Ugandan biological data, a strategic asset in the age of biosecurity.
Quality vs. Cost: China offers infrastructure (hospitals); the US offers “innovation” (Gilead drugs, Zipline drones). The US narrative is that American partnership brings “modernization” and “quality,” implicitly characterizing Chinese aid as inferior or debt-trap diplomacy.
Diplomatic Alignment: By signing this deal, President Museveni signals that despite his frequent anti-Western rhetoric, Uganda remains anchored in the Western security architecture regarding biological threats. The $1.7 billion package is the “rent” the US pays to keep Uganda out of China’s total orbit in the sensitive domain of biosecurity.
The Risks
The 2025 US-Uganda health deal is a masterclass in the new “transactional diplomacy.” It successfully operationalizes the “America First” vision: it reduces long-term US liabilities by forcing co-investment; it benefits US corporations like Gilead and Zipline; it empowers culturally aligned Faith-Based Organizations; and it secures strategic biodata for US national security.
However, the risks are profound.
Fiscal Fragility
The assumption that Uganda can mobilize $577 million in new domestic funding is optimistic at best. If the GoU fails to pay the salaries of the thousands of transitioned health workers, the system could collapse, leading to a resurgence of HIV and malaria that respects no borders.
Human Rights Regression
By stripping away human rights conditionalities and empowering FBOs, the deal abandons LGBTQ+ Ugandans. This moral retreat may have epidemiological consequences, as key populations are driven underground, fueling new transmission chains.
Institutional Erosion
The dismantling of USAID and the reliance on “lean” bilateral deals removes the technical scaffolding of development. Without the deep, on-the-ground expertise of development professionals, the billions poured into commodities may be wasted through supply chain leakage and mismanagement.
Comparative Models
| Feature | Traditional Model (Pre-2025 / USAID) | “America First” Model (Dec 2025 / State Dept) |
|---|---|---|
| Lead Agency | USAID (Development Focus) | Bureau of Global Health Security (Security Focus) |
| Primary Implementers | International NGOs (e.g., Chemonics, Care) | Host Gov & FBOs (e.g., UCMB, GoU) |
| Funding Structure | Grants/Cooperative Agreements (Process-heavy) | Bilateral Compacts (Performance-based) |
| Primary Goal | Human Development / Poverty Reduction | US National Security / Export Promotion |
| Procurement | Global Sourcing / Generics (Best Value) | “Buy American” (US Innovation Focus) |
| Key Population Policy | Inclusive (Rights-based focus on LGBTQ+) | Restrictive (“Frontline only”, FBO preference) |
| Time Horizon | Open-ended (Continuous cycles) | Time-bound (5-year transition to self-reliance) |
Corporate Players
| US Corporate Partner | Product/Service | Strategic Function in AFGHS |
|---|---|---|
| Gilead Sciences | Lenacapavir (HIV Injectable) | Biomedical Export: Subsidized market entry for high-value US IP; “bending the curve” of the epidemic. |
| Zipline Intl. Inc. | Drone Logistics / Robotics | Tech Export: Countering Chinese infrastructure with US “AI/Robotics” branding; rapid outbreak response. |
| Ginkgo Bioworks | Biosecurity / Surveillance | Biodefense: Establishing “biothreat radar” (noted in regional context, applicable to surveillance pillar). |
| Abbott / Cepheid | Diagnostics (Rapid Tests) | Manufacturing Support: Continued procurement of US-made test kits ($350m+ globally) to support US jobs. |
Uganda’s Fiscal Challenge
| Fiscal Category | Commitment | Risk Factor |
|---|---|---|
| New Domestic Spend | $577 Million (over 5 years) | High: Requires ~$115m/year in new revenue amid debt distress. |
| Workforce Absorption | Absorption of 14,000+ CHEWs & Staff | Critical: Recurrent wage bill expansion is politically difficult to reverse; strike risk if payments fail. |
| Commodity Management | Full assumption of Supply Chain costs | Medium: Risk of corruption/theft at National Medical Stores without USAID oversight. |
The USAID Collapse
The year 2025 began with immediate executive action. On January 20, inauguration day, the Trump administration issued a sweeping executive order freezing all foreign assistance and mandating a 90-day review. This “stop-work” order sent shockwaves through the global development community.
In Uganda, HIV clinics managed by partners began to ration drugs, and outreach programs for the youth were suspended.
By March 28, 2025, the administration signaled its intent to permanently dissolve USAID. The justification was rooted in the “America First” ideology: that the agency was a bloated relic of the Cold War, infested with “woke” bureaucrats who prioritized social engineering over American interests.
The Purge: In the subsequent months, thousands of “experts”—contracting officers, technical specialists, and program managers—were dismissed or placed on administrative leave. The agency, which had a staff of 10,000, was reduced to its statutory minimum.
The Transfer: On July 1, 2025, the remaining functions were formally transferred to the Department of State. The “Bureau for Global Health” at USAID ceased to exist, replaced by the “Bureau of Global Health Security and Diplomacy” (GHSD) at State.
In Uganda, USAID was not just a funder—it was a parallel government. It operated in districts where the central government was absent.
The “Shadow Revolution” saw the termination of 86% of USAID awards globally. In Uganda, massive integrated health projects (often valued at $50-$100 million) were abruptly ended.
This created a chaotic interim period (January to September 2025) where service delivery relied on “limited waivers” and emergency bridge funding. The new $1.7 billion deal is effectively the restructuring of the debris left by this explosion.
It picks up the pieces—specifically the commodities and the doctors—while leaving the “soft” development work (democracy governance, education, civil society support) in the ashes.
Faith-Based Infrastructure
The elevation of Faith-Based Organizations in the AFGHS is a calculated political and operational maneuver. In Uganda, religion and health are inextricably linked, but the US pivot to FBOs changes the power dynamics of the sector.
The Uganda Catholic Medical Bureau (UCMB) is a behemoth. It manages a network of 33 hospitals and over 260 lower-level clinics. The Uganda Protestant Medical Bureau (UPMB) has a similar reach.
Historically, USAID funded these groups, but often as sub-grantees to secular primes (like Catholic Relief Services or secular firms). The new deal proposes funding them directly.
Capacity Assessment: The UCMB has long argued for this direct funding, citing their deep roots in the community and lower administrative costs. The US administration agrees, viewing them as “high-impact” partners.
The Waiver Precedent: During the 2025 freeze, UCMB facilities were among the few granted waivers to continue ART (Antiretroviral Therapy) distribution. This signaled their privileged status early on.
The alignment is not just operational—it’s ideological. The Trump administration’s base includes evangelical Christians who have long been critical of US foreign aid supporting “liberal” causes (abortion, LGBTQ+ rights) abroad.
By empowering the Church in Uganda, the US strengthens the very institutions that have championed “traditional family values” and, by extension, the Anti-Homosexuality Act.
The danger lies in the populations that FBOs won’t serve. While UCMB hospitals are generally non-discriminatory in theory, the stigma within religious facilities against sex workers and LGBTQ+ individuals is well-documented.
If the secular NGOs (who often ran “moonlight clinics” specifically for key populations) are defunded, there’s no “safe harbor” left. The “America First” strategy assumes that “general population” coverage is sufficient to control the epidemic—a hypothesis that contradicts twenty years of HIV epidemiology.
Can Uganda Pay?
The “Stronger” pillar of the AFGHS demands “co-investment.” The $577 million figure is the price of admission for Uganda. But is it payable?
Uganda’s fiscal year 2024/2025 budget was already strained. The debt-to-GDP ratio hovers around 50%, and interest payments consume a massive chunk of domestic revenue.
The Source of Funds: The GoU has pledged to “increase domestic health expenditures.” This likely implies a reallocation from other sectors or an optimistic projection of oil revenues (which have faced repeated delays).
The “Head-Fake”: Critics argue that Uganda has signed similar pledges before (e.g., the Abuja Declaration) and failed to meet them. However, the new US deal has “teeth.” The funding is “time-bound” and performance-based. If the GoU doesn’t release the funds for the health worker salaries, the US might withhold the drug shipments.
The transition plan envisions the US “gradually” stepping back over five years:
- Year 1-2: US pays 100% of frontline costs
- Year 3-5: GoU assumes increasing share (e.g., 20%, 50%, 80%)
If Uganda hits a macroeconomic shock (e.g., a drop in oil prices, a drought), the first budget line to be cut is often the counterpart funding for development projects.
In this scenario, the “rigid” structure of the America First deal could become a trap. The US would face a choice: enforce the deal and let the health system crash, or blink and restore funding (violating the “America First” principle). The MOU is a high-stakes game of chicken between Washington and Kampala.
The December 2025 agreement is a mirror of the world it was born into: fractured, transactional, and competitive. It strips the romance from global health. There’s no talk of “global citizenship” or “universal rights.” There is only the cold calculus of “biosecurity,” “market access,” and “sovereign responsibility.”
For the Trump administration, it’s a proof-of-concept. It demonstrates that the US can remain a global player without the “bloat” of the old aid industrial complex. It shows that it can mobilize American industry and counter China without spending endless billions in open-ended grants.
For Uganda, it’s a survival raft in a stormy sea. With the traditional aid architecture collapsing, the Museveni government grabbed the only lifeline available—even if it came with heavy chains of co-investment and commercial dependency.
The ultimate verdict on the “Kampala Accord” will not be written in diplomatic cables, but in the viral load counts of patients in Gulu and Mbarara in 2030. If the transition works, Uganda emerges with a sovereign, self-funded health system. If it fails, the “America First” experiment will have been purchased at the cost of millions of Ugandan lives.
Our articles make government information more accessible. Please consult a qualified professional for financial, legal, or health advice specific to your circumstances.